Results 241 to 250 of about 295,251 (340)

Is End-Stage Renal Disease Tumor Suppressive? Dispelling the Myths. [PDF]

Cancers (Basel)
Migita T.
europepmc   +1 more source

RISKS AND COSTS OF DEVELOPING END-STAGE RENAL DISEASE AFTER HEART TRANSPLANTATION

, 1998
John Hornberger, Jennie H. Best, Mark McClellan   +2 more
openalex   +1 more source

Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms

Advanced NanoBiomed Research, EarlyView.
Cancer cell membrane‐based nanoparticles (CCM‐NPs) and cancer cell‐derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for targeted cancer treatment. Advances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment.
Wei Zhang, Jingjing Wang, Long Ngo, Li Li, Yuling Wang   +4 more
wiley   +1 more source

SPECT/CT in addition to subtraction parathyroid scintigraphy in hyperparathyroidism: diagnostic performance in a cohort of predominantly end-stage renal disease patients. [PDF]

EJNMMI Res
Jitrapinate W, Raruenrom Y, Wongsurawat N, Sa-Ngiamwibool P, Theerakulpisut D.   +4 more
europepmc   +1 more source

Immunoengineering of a Photocaged 5´‐triphosphate Oligoribonucleotide Ligand for Spatiotemporal Control of RIG‐I Activation in Cancer

Angewandte Chemie International Edition, EarlyView.
This study presents a method for precise control of RIG‐I (retinoic acid inducible gene I), an innate immune receptor of RNA that, when activated, induces anti‐tumor immune responses and cancer cell death. By incorporating photocage modifications into RNA ligands, we enable a spatially and temporally regulated immune response and offer a targeted ...
Sandra Anika Lewash, Vivien Rose McKenney, Christine Wuebben, Janos Ludwig, Racha Hosni, Dirk Radzey, Marieta I. Toma, Eva Bartok, Martin Schlee, Thomas Zillinger, Alexander Heckel, Gunther Hartmann   +11 more
wiley   +1 more source

Cost Analysis of End-Stage Renal Disease in Pediatric Patients in Greece. [PDF]

Healthcare (Basel)
Ntais C, Loizou K, Panagiotakis C, Kontodimopoulos N, Fanourgiakis J.   +4 more
europepmc   +1 more source

Significantly higher rates of KIDINS220 polymorphisms in patients with obesity and end-stage renal disease. [PDF]

Obes Pillars
Richards J, Dorand MF, Paszkowiak M, Ahmed S, McCorkle C, Kathuria P.   +5 more
europepmc   +1 more source

Simultaneous pancreas-kidney transplantation in hispanic recipients with type I diabetes mellitus and end-stage renal disease

, 1997
Gaetano Ciancio, George W. Burke, Carmen Gómez, L. Olson, Violet Esquenazi, J. Miller   +5 more
openalex   +1 more source

Outcomes of Acute Invasive Fungal Rhinosinusitis Patients Treated with Retrobulbar Amphotericin B Injections versus Orbital Exenteration

International Forum of Allergy &Rhinology, EarlyView.
Jakob L. Fischer, Nikitha Kosaraju, Katherine M. Lucarelli, Christine R. Wells, Connie M. Sears, Reem Karmouta, Ashley S. Shirriff, Maxwell Weng, Jeffrey D. Suh, Jivianne T. Lee, Daniel M. Beswick, Daniel B. Rootman, Marilene B. Wang   +12 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal, Ingrid E. Lundberg, Yeong‐Wook Song, Aziz Shaibani, Victoria P. Werth, Michael A. Maldonado   +5 more
wiley   +1 more source